Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging

Radiology

Volumn 256, Issue 1, 2010, Pages 151-158

  Motosugi, Utaroh ^a   Ichikawa, Tomoaki ^a   Sou, Hironobu ^a   Sano, Katsuhiro ^a   Tominaga, Licht ^a   Muhi, Ali ^a   Araki, Tsutomu ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EOB PRIMOVIST; GADOXETIC ACID; UNCLASSIFIED DRUG;

ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; HISTOPATHOLOGY; LIVER; LIVER ARTERIOGRAPHY; LIVER CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL PHLEBOGRAPHY; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PSEUDOLESION; SIGNAL NOISE RATIO;

AGED; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953926075     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10091885     Document Type: Article

References (20)

1. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208-1236.
2. Study Group of Evidence Based Practice Guideline for Liver Cancer. Liver cancer practice guideline. Tokyo, Japan: Kanehara, 2005;69.
3. Sherman M. Diagnosis of small hepatocellular carcinoma. Hepatology 2005;42(1):14-16.
4. Hwang SH, Yu JS, Kim KW, Kim JH, Chung JJ. Small hypervascular enhancing lesions on arterial phase images of multiphase dynamic computed tomography in cirrhotic liver: fate and implications. J Comput Assist Tomogr 2008;32(1):39-45.
5. Ahn JH, Yu JS, Hwang SH, Chung JJ, Kim JH, Kim KW. Nontumorous arterioportal shunts in the liver: CT and MRI findings considering mechanisms and fate. Eur Radiol 2010;20(2):385-394.
6. Mori K, Yoshioka H, Itai Y, et al. Arterioportal shunts in cirrhotic patients: evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide. AJR Am J Roentgenol 2000;175(6):1659-1664.
7. World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ 2001;79(4):373-374.
8. Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y. Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography-radiologic-pathologic correlation. Radiology 2009;252(2):605-614.
9. Ueda K, Matsui O, Kawamori Y, et al. Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 1998;206(1):161-166. (Pubitemid 28063001)
10. Yumoto Y, Jinno K, Tokuyama K, et al. Hepatocellular carcinoma detected by iodized oil. Radiology 1985;154(1):19-24. (Pubitemid 15196277)
11. Yu JS, Kim KW, Jeong MG, Lee JT, Yoo HS. Nontumorous hepatic arterial-portal venous shunts: MR imaging findings. Radiology 2000;217(3):750-756.
12. Okuda K, Musha H, Yamasaki T, et al. Angiographic demonstration of intrahepatic arterio-portal anastomoses in hepatocellular carcinoma. Radiology 1977;122(1):53-58. (Pubitemid 8011556)
13. Matsuo M, Kanematsu M, Kondo H, et al. Arterioportal shunts mimicking hepatic tumors with hyperintensity on T2-weighted MR images. J Magn Reson Imaging 2002;15(3):330-333.
14. Ward J, Guthrie JA, Sheridan MB, et al. Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol 2008;26(26):4304-4310.
15. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 2009;193(4):1053-1060.
16. Saito K, Kotake F, Ito N, et al. Gd-EOBDTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005;4(1):1-9.
17. Fujita M, Yamamoto R, Takahashi M, et al. Paradoxic uptake of Gd-EOB-DTPA by hepatocellular carcinoma in mice: quantitative image analysis. J Magn Reson Imaging 1997;7(4):768-770.
18. Fujita M, Yamamoto R, Fritz-Zieroth B, et al. Contrast enhancement with Gd-EOB-DTPA in MR imaging of hepatocellular carcinoma in mice: a comparison with superparamagnetic iron oxide. J Magn Reson Imaging 1996;6(3):472-477.
19. Muhi A, Ichikawa T, Motosugi U, et al. High-b-value diffusion-weighted MR imaging of hepatocellular lesions: estimation of grade of malignancy of hepatocellular carcinoma. J Magn Reson Imaging 2009;30(5):1005-1011.
20. Li CS, Chen RC, Lii JM, et al. Magnetic resonance imaging appearance of well-differentiated hepatocellular carcinoma. J Comput Assist Tomogr 2006;30(4):597-603.